NDATOPICALAEROSOL, FOAM
Approved
Oct 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
8
Data completeness
6/8 — Strong
ENSTILAR (calcipotriene and betamethasone dipropionate) by Leo Pharma is d3 analog and betamethasone dipropionate as a synthetic corticosteroid. First approved in 2015.
Drug data last refreshed 9h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENSTILAR is a fixed-dose combination topical foam containing calcipotriene (a vitamin D3 analog) and betamethasone dipropionate (a synthetic corticosteroid) approved for plaque psoriasis. The exact mechanisms of action in psoriasis treatment remain incompletely understood, though both components have established pharmacologic effects on skin inflammation and keratinocyte differentiation. It represents a dual-mechanism approach to moderate-to-severe plaque psoriasis delivered via innovative aerosol foam formulation.
$8.0MPart D
Peak5.5 years to LOEPeak-stage product with stable, modest Medicare utilization; brand team likely focused on market penetration and retention rather than aggressive growth.
Mechanism of Action
D3 analog and betamethasone dipropionate as a synthetic corticosteroid. However, while their pharmacologic and clinical effects are known, the exact mechanisms of their actions in the treatment of plaque psoriasis are unknown.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (8)
A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis
Started Nov 2021
6 enrolled
Nail Psoriasis
Assessing the Efficacy of Image-guided Laser-assisted Enstilar® Delivery for Treatment of Psoriatic Nails
Started Oct 2020
11 enrolled
Nail Psoriasis
Taltz in Combination With Enstilar for Psoriasis
Started Apr 2020
25 enrolled
Psoriasis
Observational Study in Patients With Nail Psoriasis Treated With Enstilar® to Assess the Severity Change and the Quality of Life
Started Mar 2019
10 enrolled
Nail Psoriasis
Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
Started Jan 2019
30 enrolled
Psoriasis
Worked on ENSTILAR at Leo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.